Clarius Group’s Karuna Therapeutics KRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
– Sell
-69,248
Closed -$21.9M – 503
2023
Q4
$21.9M Sell
69,248
-29,973
-30% -$5.83M 1.82% 12
2023
Q3
$16.8M Hold
99,221
– – 1.6% 14
2023
Q2
$21.5M Sell
99,221
-20,475
-17% -$4.39M 1.66% 11
2023
Q1
$21.7M Buy
119,696
+9,283
+8% +$1.78M 1.85% 11
2022
Q4
$21.7M Buy
110,413
+447
+0.4% +$95.9K 1.95% 10
2022
Q3
$24.7M Buy
109,966
+104,514
+1,917% +$21.2M 2.47% 10
2022
Q2
$690K Buy
+5,452
New +$627K 0.07% 173

Other funds holding KRTX

Clarius Group's KRTX Position: Q1 2024 in Review

Clarius Group sold out of Karuna Therapeutics (KRTX) in Q1 2024, closing a stake of 69,248 shares — an estimated $21.9M sold.

Clarius Group first reported a position in KRTX in Q2 2022 and held it in 7 quarters. The position peaked at $24.7M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • Clarius Group reported no remaining Karuna Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Clarius Group sold 69,248 Karuna Therapeutics shares in Q1 2024, an estimated $21.9M.
  • Clarius Group first reported a position in Karuna Therapeutics in Q2 2022 and held it in 7 quarters.
  • Clarius Group's Karuna Therapeutics position peaked at $24.7M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics as of Q1 2024.

Based on Clarius Group's 13F filing for Q1 2024, filed 17 Apr 2024.